This content is from: Home

Pharma companies exposed to transfer pricing challenges

The interaction of Poland’s transfer pricing rules and reimbursement law means the pharmaceutical industry is faced with complex compliance demands, explains Aneta Blazejewska-Gaczynska and Slawomir Buszko of Ernst & Young.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.

REQUEST ACCESS

Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial

Related